Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OSI says Tarceva will meet 2007 US sales targets
Genentech has reported that third quarter US net sales for Tarceva were approximately $101 million, a 1% increase over the same quarter of the last year. OSI stated
Genentech has reported that third quarter US net sales for Tarceva were approximately $101 million, a 1% increase over the same quarter of the last year. OSI stated
JEGC retains a non-exclusive right to purchase the shares under the agreement, which remains in effect subject to both parties’ right to terminate the agreement. Earlier, TLC Vision
Innovive expects to begin enrollment in its pivotal Phase II study in the fourth quarter of 2007. Innovive has recently reached an agreement with the FDA on a
The all-natural medicine has been approved in China for external use to treat human papillomavirus and herpes simplex virus. Tests have shown an inhibitory effect on the growth
The drug, XP21510, is a non-hormonal, oral product for the potential treatment of women diagnosed with menorrhagia, or heavy menstrual bleeding. It is estimated that 9 to 14%
The payment arises from an agreement between the two companies and reflects progress in the development of bazedoxifene, a selective estrogen receptor modulator. Bazedoxifene is a synthetic drug
The approval is based on data from a prospective Phase I pharmacokinetic trial in patients with varying degrees of kidney impairments. The results of the study satisfy a
The analyses of Lialda’s 303 trial, a long-term, Phase III, open-label 12-14 month extension study, will be presented at the American College of Gastroenterology meeting in Philadelphia. A
The multi-center Phase III trial compared Aloxi (palonosetron hydrochloride) injection to placebo for the prevention of post-operative nausea and vomiting (PONV) following elective inpatient gynecologic or breast surgery.
The acquisition will expand Apria’s service offering by creating a nationwide home infusion provider. The transaction also enables Apria to immediately enter the large and rapidly-growing specialty pharmaceutical